Merck Announces a Non-Binding MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology
News Release
- Merck announces a non-binding MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies
- Integrates company’s BioContinuum™ Platform in Mycenax’s Contract Development and Manufacturing Services (CDMO) for maximum safety, control, transparency, and repeatability
- Collaboration aims to enhance process intensification, advance towards BioProcessing 4.0 and continuous bioprocessing
Darmstadt, Germany, January 24, 2024 - Merck, a leading science and technology company, announced that the Life Science business sector entered into a non-binding Memorandum of Understanding (MoU) with Mycenax Biotech to explore cooperation to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets. The MoU explores integration of Merck’s BioContinuum™ Platform in the entire bioprocessing spectrum for Mycenax’s customers, followed by automation and digitalization of processes.
"Digital transformation in biomanufacturing is creating a paradigm shift towards a bioprocessing facility-of-the-future that is data-intensified, connected and seamless in continuous processing,” said Gladys Wang, Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck. “By combining the strengths of Merck and Mycenax in Contract Development and Manufacturing Services, we aim to accelerate the development of new products and process innovations. This will enhance resilience in both research and production.”
As part of the MoU, Merck will explore with Mycenax the provision of its extensive support including consultation, technical assistance, and training, ensuring Mycenax receives expert guidance for optimal performance. Recognizing the importance of economic viability, the collaboration will also seek ways to incorporate in-depth cost modelling for better process economics. This strategic analysis aims to enhance cost-effectiveness in next generation bioprocessing.
"Mycenax consistently seeks better solutions and areas for optimization. The integration of continuous processing and Industry 4.0 is not only a future mainstream trend but also possesses the potential for continuous growth," said Pei-Jiun Chen, Ph.D., Chairman/CEO and President of Mycenax. "The collaboration with Merck aims to provide innovative continuous processing solutions in the market, to boost our international standing and cater to diverse biopharmaceutical needs."
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
Comunicati stampa più recenti
Per continuare a leggere, autenticati o crea un account.
Non hai un Account?